ATE449106T1 - Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben - Google Patents
Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselbenInfo
- Publication number
- ATE449106T1 ATE449106T1 AT97916024T AT97916024T ATE449106T1 AT E449106 T1 ATE449106 T1 AT E449106T1 AT 97916024 T AT97916024 T AT 97916024T AT 97916024 T AT97916024 T AT 97916024T AT E449106 T1 ATE449106 T1 AT E449106T1
- Authority
- AT
- Austria
- Prior art keywords
- fibroblast
- applications
- protein alpha
- activate protein
- isolated dimeric
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000002950 fibroblast Anatomy 0.000 title 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 abstract 2
- 108010072257 fibroblast activation protein alpha Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/619,280 US5767242A (en) | 1994-04-20 | 1996-03-18 | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| PCT/US1997/004215 WO1997034927A1 (en) | 1996-03-18 | 1997-03-12 | Isolated dimeric fibroblast activation protein alpha, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE449106T1 true ATE449106T1 (de) | 2009-12-15 |
Family
ID=24481231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97916024T ATE449106T1 (de) | 1996-03-18 | 1997-03-12 | Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US5767242A (de) |
| EP (1) | EP0960127B1 (de) |
| JP (1) | JP4102441B2 (de) |
| KR (1) | KR20000064655A (de) |
| CN (1) | CN1214052A (de) |
| AT (1) | ATE449106T1 (de) |
| AU (1) | AU729369B2 (de) |
| BG (1) | BG102781A (de) |
| BR (1) | BR9708100A (de) |
| CA (1) | CA2242342C (de) |
| CZ (1) | CZ299698A3 (de) |
| DE (1) | DE69739665D1 (de) |
| DK (1) | DK0960127T3 (de) |
| EE (1) | EE03693B1 (de) |
| ES (1) | ES2334183T3 (de) |
| HU (1) | HUP0104468A3 (de) |
| IL (1) | IL125124A0 (de) |
| NO (1) | NO984298L (de) |
| NZ (2) | NZ331758A (de) |
| PL (1) | PL328947A1 (de) |
| SK (1) | SK126798A3 (de) |
| TR (1) | TR199801845T2 (de) |
| WO (1) | WO1997034927A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| HK1046846A1 (zh) * | 1999-05-25 | 2003-01-30 | Point Therapeutics, Inc. | 包含boroproline的抗肿瘤复合物 |
| EP1806138A1 (de) * | 1999-05-25 | 2007-07-11 | Point Therapeutics, Inc. | Anti-tumor präparate enthaltend boroprolin verbindungen |
| US20030092890A1 (en) * | 1999-07-28 | 2003-05-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| JP2004536835A (ja) * | 2001-07-09 | 2004-12-09 | アフトン コーポレーション | 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止 |
| US7691967B2 (en) | 2002-04-30 | 2010-04-06 | Trustees Of Tufts College | Smart pro-drugs of serine protease inhibitors |
| WO2004004661A2 (en) * | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| US7309774B2 (en) | 2003-02-07 | 2007-12-18 | The Board Of Regents Of The University Of Oklahoma | Antiplasmin cleaving enzyme |
| US20080057491A1 (en) * | 2003-02-07 | 2008-03-06 | Mckee Patrick A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use |
| US7235376B2 (en) * | 2003-03-28 | 2007-06-26 | Receptor Biologix, Inc. | Gastrin hormone immunoassays |
| US20060020119A1 (en) * | 2004-03-29 | 2006-01-26 | Stephen Grimes | Monoclonal antibodies to gastrin hormone |
| WO2005071073A1 (en) * | 2004-01-09 | 2005-08-04 | Point Therapeutics, Inc. | Fap compositions and the use thereof for immunomodulation |
| US20090010919A1 (en) * | 2004-07-29 | 2009-01-08 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap) |
| EP2567974A3 (de) | 2004-09-22 | 2013-05-22 | Cancer Advances, Inc., | Monoklonale Antikörper gegen Progastrin |
| US20090238862A1 (en) * | 2004-10-27 | 2009-09-24 | Wen-Tien Chen | Methods and Compositions for Seprase Inactivation |
| PL1824991T3 (pl) | 2004-11-24 | 2016-08-31 | Techlab Inc | Urządzenie oraz sposób do wykrywania analitów |
| US8067248B2 (en) | 2005-12-14 | 2011-11-29 | Luwig Institute for Cancer Research | Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| PT2035581E (pt) * | 2006-06-21 | 2012-12-06 | Scripps Research Inst | Composição de adn contra o antigénio do estroma tumoral fap e métodos de utilização desta |
| CA2753884A1 (en) | 2009-02-27 | 2010-09-02 | Trustees Of Tufts College | Soft protease inhibitors, and pro-soft forms thereof |
| CN104884091B (zh) | 2012-12-28 | 2021-07-20 | 科比欧尔斯公司 | 最低毒性的药物前体 |
| CN103267852B (zh) * | 2013-05-15 | 2015-03-25 | 中国医学科学院北京协和医院 | 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途 |
| IL325256A (en) | 2014-06-13 | 2026-02-01 | Bach Biosciences Llc | FAP-activated medical materials and related uses |
| CN105859866B (zh) * | 2016-05-27 | 2019-08-13 | 郑州大学 | Fap来源的抗肿瘤ctl表位肽p265及其应用 |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| IL271427B2 (en) | 2017-06-15 | 2025-08-01 | Cancer Advances Inc | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| AU2021405744A1 (en) | 2020-12-22 | 2023-08-03 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1320734C (en) * | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| US5587299A (en) * | 1994-04-20 | 1996-12-24 | Memorial Sloan-Kettering Cancer Center | Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof |
-
1996
- 1996-03-18 US US08/619,280 patent/US5767242A/en not_active Expired - Lifetime
-
1997
- 1997-03-12 CA CA2242342A patent/CA2242342C/en not_active Expired - Fee Related
- 1997-03-12 EP EP97916024A patent/EP0960127B1/de not_active Expired - Lifetime
- 1997-03-12 BR BR9708100-0A patent/BR9708100A/pt not_active Application Discontinuation
- 1997-03-12 CZ CZ982996A patent/CZ299698A3/cs unknown
- 1997-03-12 AU AU23302/97A patent/AU729369B2/en not_active Ceased
- 1997-03-12 DE DE69739665T patent/DE69739665D1/de not_active Expired - Lifetime
- 1997-03-12 WO PCT/US1997/004215 patent/WO1997034927A1/en not_active Ceased
- 1997-03-12 NZ NZ331758A patent/NZ331758A/xx unknown
- 1997-03-12 DK DK97916024.9T patent/DK0960127T3/da active
- 1997-03-12 JP JP53359297A patent/JP4102441B2/ja not_active Expired - Fee Related
- 1997-03-12 EE EE9800306A patent/EE03693B1/xx not_active IP Right Cessation
- 1997-03-12 KR KR1019980707369A patent/KR20000064655A/ko not_active Ceased
- 1997-03-12 PL PL97328947A patent/PL328947A1/xx unknown
- 1997-03-12 ES ES97916024T patent/ES2334183T3/es not_active Expired - Lifetime
- 1997-03-12 SK SK1267-98A patent/SK126798A3/sk unknown
- 1997-03-12 CN CN97193176A patent/CN1214052A/zh active Pending
- 1997-03-12 TR TR1998/01845T patent/TR199801845T2/xx unknown
- 1997-03-12 AT AT97916024T patent/ATE449106T1/de active
- 1997-03-12 IL IL12512497A patent/IL125124A0/xx unknown
- 1997-03-12 HU HU0104468A patent/HUP0104468A3/hu unknown
- 1997-10-01 US US08/940,391 patent/US5965373A/en not_active Expired - Lifetime
-
1998
- 1998-09-17 NO NO984298A patent/NO984298L/no not_active Application Discontinuation
- 1998-09-18 BG BG102781A patent/BG102781A/xx unknown
-
1999
- 1999-05-03 NZ NZ335543A patent/NZ335543A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ335543A (en) | 2001-03-30 |
| HUP0104468A3 (en) | 2004-10-28 |
| IL125124A0 (en) | 1999-01-26 |
| EE03693B1 (et) | 2002-04-15 |
| CA2242342C (en) | 2013-05-14 |
| EP0960127A4 (de) | 2004-09-08 |
| BR9708100A (pt) | 2000-01-04 |
| JP4102441B2 (ja) | 2008-06-18 |
| DK0960127T3 (da) | 2010-03-29 |
| PL328947A1 (en) | 1999-03-01 |
| US5767242A (en) | 1998-06-16 |
| NO984298D0 (no) | 1998-09-17 |
| EP0960127A1 (de) | 1999-12-01 |
| HUP0104468A2 (hu) | 2002-04-29 |
| AU729369B2 (en) | 2001-02-01 |
| CA2242342A1 (en) | 1997-09-25 |
| BG102781A (en) | 1999-09-30 |
| CZ299698A3 (cs) | 1999-01-13 |
| AU2330297A (en) | 1997-10-10 |
| EP0960127B1 (de) | 2009-11-18 |
| EE9800306A (et) | 1999-02-15 |
| WO1997034927A1 (en) | 1997-09-25 |
| US5965373A (en) | 1999-10-12 |
| NZ331758A (en) | 2000-01-28 |
| KR20000064655A (ko) | 2000-11-06 |
| TR199801845T2 (xx) | 1998-12-21 |
| NO984298L (no) | 1998-09-17 |
| DE69739665D1 (de) | 2009-12-31 |
| ES2334183T3 (es) | 2010-03-05 |
| JP2000507100A (ja) | 2000-06-13 |
| CN1214052A (zh) | 1999-04-14 |
| SK126798A3 (en) | 1999-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69739665D1 (de) | Isoliertes, dimerisches fibroblasten-aktivierendes protein alpha und anwendungen desselben | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| ES2195970T3 (es) | L-ribavirina y usos de la misma. | |
| ES2184149T3 (es) | Paclitaxeles 6-tio sustituidos. | |
| ATE280826T1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| DE69840474D1 (de) | Temperaturunempfindlicher siliziumoszillator und daraus erzeugte präzesionsspannungsreferenz | |
| DE69832158D1 (de) | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 | |
| NO971875D0 (no) | Cathepsin 02 protease | |
| DE69435307D1 (de) | Bazillus Thuringiensis und dessen insektizide Proteine | |
| AR016981A2 (es) | Polipeptidos sinteticos | |
| ATE253113T1 (de) | Für ein fibroblasten-aktivierungsprotein kodierende nukleinsäure und verwendungen dafür | |
| PT929299E (pt) | 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos | |
| TR199802504T2 (xx) | N�rotoksik yaralanmalar�n tedavisi i�in bukminsterflirin kullan�lmas�. | |
| ATE356212T1 (de) | O-fukosyltransferase | |
| BG101787A (en) | Aprotinine options having improved properties | |
| ES2175356T3 (es) | Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares. | |
| DK1012175T3 (da) | Peptid med affinitet til koagulationsfaktor VIII | |
| EP0826764A3 (de) | Verwendung substituierter 2-Acetylbenzofurane als Riechstoffe | |
| EA200000875A1 (ru) | Белки, взаимодействующие с каспазой-8 | |
| DE69842091D1 (de) | Frazzled Nukleotidsequenzen, Expressions- produkte, Zusammensetzungen und Verwendungen | |
| ATE250340T1 (de) | 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele | |
| BG102937A (en) | Zona pelucida proteins as contraceptives | |
| TR200103662T2 (tr) | Yeni kalpainler ve bunların kullanılması | |
| BR9803717A (pt) | ácidos indol-2-carbocìlicos substituìdos como inibidores de glucosil transferase. | |
| DK1133297T3 (da) | Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0960127 Country of ref document: EP |